Bora Acquires MacroGenics' Manufacturing Operations

Bora Pharmaceuticals announced on May 12, 2026, that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc. for a total consideration of US$122.5 million, with a potential contingent consideration of up to $5 million. The transaction includes a biologics drug substance manufacturing facility in Rockville, Maryland, and a warehousing center in Frederick, Maryland. Upon closing, Bora Pharmaceuticals will enter into a long-term CDMO Service Agreement with MacroGenics. Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals, stated that this acquisition is a pivotal step in strengthening Bora Pharmaceuticals' integrated biologics CDMO platform in the United States. Bora Pharmaceuticals intends to leverage the Rockville Site in cooperation with Tanvex BioPharma to scale its end-to-end biologics platform. The Rockville facility has been inspected by both the United States — Food and Drug Administration and Japan's Japan — Pharmaceuticals and Medical Devices Agency.